IL-33 in clinical practice: Size matters?

Journal of Allergy and Clinical Immunology

Volumn 140, Issue 2, 2017, Pages 381-383

  Morita, Hideaki ^a,b   Nakae, Susumu ^c   Saito, Hirohisa ^a   Matsumoto, Kenji ^a  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

alarmin; biological activity; IL 33; innate lymphoid cell

Indexed keywords

ADENOSINE TRIPHOSPHATE; CASPASE 7; CYTOKINE ANTIBODY; INTERLEUKIN 33; PURINERGIC RECEPTOR; IL33 PROTEIN, HUMAN;

ALLERGIC DISEASE; APOPTOSIS; CALCIUM TRANSPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CYTOKINE RELEASE; CYTOPLASM; EDITORIAL; EXTRACELLULAR SPACE; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INTRACELLULAR SPACE; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; ANTAGONISTS AND INHIBITORS; DISEASE PREDISPOSITION; DRUG DEVELOPMENT; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY;

DISEASE SUSCEPTIBILITY; DRUG DISCOVERY; HUMANS; INTERLEUKIN-33; MOLECULAR TARGETED THERAPY;

EID: 85019984871     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2017.03.042     Document Type: Editorial

References (10)

1. Akdis, M., Aab, A., Altunbulakli, C., Azkur, K., Costa, R.A., Crameri, R., et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor beta, and TNF-α: receptors, functions, and roles in diseases. J Allergy Clin Immunol 138 (2016), 984–1010.
2. Martin, N.T., Martin, M.U., Interleukin 33 is a guardian of barriers and a local alarmin. Nat Immunol 17 (2016), 122–131.
3. Morita, H., Moro, K., Koyasu, S., Innate lymphoid cells in allergic and nonallergic inflammation. J Allergy Clin Immunol 138 (2016), 1253–1264.
4. Takeda, T., Unno, H., Morita, H., Futamura, K., Emi-Sugie, M., Arae, K., et al. Platelets constitutively express IL-33 protein and modulate eosinophilic airway inflammation. J Allergy Clin Immunol 138 (2016), 1395–1403.e6.
5. Luthi, A.U., Cullen, S.P., McNeela, E.A., Duriez, P.J., Afonina, I.S., Sheridan, C., et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31 (2009), 84–98.
6. Nile, C.J., Barksby, E., Jitprasertwong, P., Preshaw, P.M., Taylor, J.J., Expression and regulation of interleukin-33 in human monocytes. Immunology 130 (2010), 172–180.
7. Kouzaki, H., Iijima, K., Kobayashi, T., O'Grady, S.M., Kita, H., The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol 186 (2011), 4375–4387.
8. Lefrancais, E., Duval, A., Mirey, E., Roga, S., Espinosa, E., Cayrol, C., et al. Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc Natl Acad Sci U S A 111 (2014), 15502–15507.
9. Lefrancais, E., Roga, S., Gautier, V., Gonzalez-de-Peredo, A., Monsarrat, B., Girard, J.P., et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A 109 (2012), 1673–1678.
10. Cohen, E.S., Scott, I.C., Majithiya, J.B., Rapley, L., Kemp, B.P., England, E., et al. Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat Commun, 6, 2015, 8327.